Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,246 across all filing types
Latest filing 2020-07-07 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed financial data about transactions and outstanding balances with related parties for the half year ended March 31, 2020. The content is focused on related party transactions and balances rather than a full annual or interim financial report. It is not an announcement of a report but a substantive disclosure document. This type of disclosure is typically classified under Regulatory Filings (RNS) as it is a regulatory compliance document providing specific transaction disclosures rather than a full financial report or management discussion.
2020-07-07 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification about the closure of the trading window for insiders ahead of the announcement of unaudited financial results for the quarter ended June 30, 2020. It references regulatory compliance with insider trading regulations and advises designated persons not to trade during the specified period. There is no actual financial data or results presented, nor is there a detailed report or analysis. The document is an announcement related to trading restrictions prior to financial results disclosure, not the financial results themselves or any other report type. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2020-06-30 English
This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the closure of the trading window for insiders ahead of the announcement of unaudited financial results for the quarter ended June 30, 2020. It references compliance with insider trading regulations and states the trading window will be closed until 48 hours after the financial results announcement. There is no actual financial data or results presented, nor is there a detailed report or analysis. The document is an announcement related to trading restrictions and timing around financial results, not the results themselves or a full report. The document length is short (2690 characters), and it serves as a regulatory announcement to the stock exchange. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice rather than a financial report or earnings release.
2020-06-30 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the non-applicability of a SEBI circular related to 'Large Corporate' classification. It includes a confirmation statement and an annexure with company details and borrowing information. There are no financial statements, earnings data, or detailed report content. The document is short (4224 characters) and serves as a regulatory compliance disclosure rather than a full report or announcement of financial results. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a compliance-related announcement that does not fit other specific categories.
2020-06-26 English
Annual Disclosure
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 173 characters, indicating it is extremely short and does not contain any report content. There is no indication of any report, announcement, or detailed information. Given the lack of content and the presence of only images, this document does not fit any detailed report category. According to the rules, such minimal content with no report text defaults to Regulatory Filings (RNS) as a fallback category.
2020-06-26 English
Dividend
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Ltd. regarding the outcome of a Board Meeting held on June 16, 2020. It includes approval of audited standalone and consolidated financial statements and results for the quarter and year ended March 31, 2020, along with the audit report. It also mentions declaration of unmodified opinion on the annual audited financial results, dividend recommendation, reappointment of auditors, appointment of an independent director as Chairman, and reconstitution of board committees. The document contains actual financial data tables for the quarter and year ended March 31, 2020, which indicates it is a comprehensive financial report for a period shorter than a full fiscal year (quarter and annual results). The presence of quarterly and annual audited financial results and detailed financial data aligns with the definition of an Interim / Quarterly Report (IR). Although it includes annual results, the focus on quarterly and year-end results with detailed financial statements and audit reports fits best under the IR category rather than a full Annual Report (10-K), which would be more extensive and comprehensive. Therefore, the document is classified as an Interim / Quarterly Report (IR). FY 2020
2020-06-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.